SK Life Science
As of the edition of 20 October 2026, SK Life Science runs 8 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cenobamate | Ends 2032 (patent) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| HTR4 5-hydroxytryptamine receptor 4 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where SK Life Science needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 31 trials led
- Inherited and neonatal: 4 trials led
- Hormones: 3 trials led